Group 1 - The company’s subsidiary, Nansen Instrumentos de Precision de Mexico, won a contract for the Nexgrid smart meter framework project in the USA, with a total contract value of $29.55 million, approximately 212 million RMB [2][5][7] - The contract involves the supply of single-phase, two-phase, and three-phase smart meters, marking a significant breakthrough for the company in the North American smart meter market [3][7] - The contract amount represents about 1.45% of the company's audited revenue for the fiscal year 2024, indicating a positive impact on the company's operational performance [3][5] Group 2 - The company plans to repurchase and cancel 5,755,371 shares, reducing its total share capital from 1,411,006,571 shares to 1,405,251,200 shares [9][14] - The share repurchase was approved in meetings held on May 28 and June 13, 2025, reflecting the company's confidence in its future development and long-term value [10][12] - The cancellation of shares is expected to enhance shareholder returns and investor confidence without significantly affecting the company's financial status or operational capabilities [15][16]

Core Viewpoint - Samsung Medical has successfully secured a contract for smart meter products in the North American market, marking a significant breakthrough in its overseas expansion efforts [1] Group 1: Contract Details - The contract was awarded to Samsung Medical's subsidiary, Nansen Instrumentos de Precision de Mexico, for the Nexgrid smart meter framework project [1] - The total contract amount is $29.555 million, equivalent to approximately 212 million RMB [1] Group 2: Strategic Implications - This contract represents a key achievement in Samsung Medical's strategy to actively explore and expand its presence in overseas markets [1] - The successful bid enhances the company's competitive advantage in the overseas smart meter market [1]